AVIDITY BIOSCIENCES INC (RNA)
US05370A1088 - Common Stock
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Investors Land RNA Even Cheaper Than Its Secondary Stock Offering
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
The company is now pivoting its technology to the cardiovascular space under a partnership with Bristol Myers Squibb.
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy
Biomarker cohort for delpacibart braxlosiran (del-brax), the first potential therapy to target DUX4, is measuring changes in DUX4 regulated biomarkers;...
Interesting RNA Put And Call Options For June 2025
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
Why Avidity Biosciences Zoomed to a 12% Gain This Week
The company's most promising pipeline program can continue unabated.
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
Avidity Biosciences Announces Proposed Public Offering of Common Stock
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024
RNA stock results show that Avidity Biosciences beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avidity Biosciences (NASDAQ:RNA) just reported results for the second quarter o...
Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights
Avidity reports positive del-zota (AOC 1044) data; demonstrated 25% increase in dystrophin production and reduction of creatine kinase levels to near normal in...
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
The company is coming up fast with a platform that could take on several of Sarepta's approved treatments.
Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in
Delpacibart zotadirsen (AOC 1044) delivered unsurpassed muscle concentrations of PMO of 200 nM after three doses of 5 mg/kg Statistically significant 37%...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
3 Stocks Doing Even Better Than Superstar Super Micro (SMCI)
These three stellar, outperforming stocks are doing better than even Super Micro Computer, which has been running away from the market.
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
These three small-cap stocks could deliver hefty returns if the central bank cuts rates.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...